ALGS vs. LENZ, ENTX, GNTA, TSBX, CDTX, AVRO, IKNA, ELUT, ASMB, and QNCX
Should you be buying Aligos Therapeutics stock or one of its competitors? The main competitors of Aligos Therapeutics include LENZ Therapeutics (LENZ), Entera Bio (ENTX), Genenta Science (GNTA), Turnstone Biologics (TSBX), Cidara Therapeutics (CDTX), AVROBIO (AVRO), Ikena Oncology (IKNA), Elutia (ELUT), Assembly Biosciences (ASMB), and Quince Therapeutics (QNCX). These companies are all part of the "medical" sector.
Aligos Therapeutics (NASDAQ:ALGS) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.
LENZ Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -607.03%. LENZ Therapeutics' return on equity of -33.12% beat Aligos Therapeutics' return on equity.
60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 16.5% of Aligos Therapeutics shares are held by insiders. Comparatively, 38.4% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Aligos Therapeutics had 3 more articles in the media than LENZ Therapeutics. MarketBeat recorded 6 mentions for Aligos Therapeutics and 3 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 0.00 beat Aligos Therapeutics' score of -0.22 indicating that LENZ Therapeutics is being referred to more favorably in the news media.
Aligos Therapeutics has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500.
Aligos Therapeutics received 18 more outperform votes than LENZ Therapeutics when rated by MarketBeat users. However, 100.00% of users gave LENZ Therapeutics an outperform vote while only 62.16% of users gave Aligos Therapeutics an outperform vote.
LENZ Therapeutics has a consensus target price of $31.33, suggesting a potential upside of 93.65%. Given LENZ Therapeutics' higher possible upside, analysts plainly believe LENZ Therapeutics is more favorable than Aligos Therapeutics.
Aligos Therapeutics has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Aligos Therapeutics and LENZ Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Aligos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aligos Therapeutics Competitors List
Related Companies and Tools
